Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEM’s FA Score shows that 1 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEM’s TA Score shows that 6 TA indicator(s) are bullish while GOSS’s TA Score has 5 bullish TA indicator(s).
CGEM (@Biotechnology) experienced а +12.06% price change this week, while GOSS (@Biotechnology) price change was +10.78% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.06%. For the same industry, the average monthly price growth was -3.25%, and the average quarterly price growth was +71.73%.
CGEM is expected to report earnings on Aug 08, 2024.
GOSS is expected to report earnings on Aug 06, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
CGEM | GOSS | CGEM / GOSS | |
Capitalization | 1.22B | 177M | 692% |
EBITDA | N/A | N/A | - |
Gain YTD | 178.214 | -18.904 | -943% |
P/E Ratio | N/A | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | N/A | N/A | - |
Total Debt | N/A | N/A | - |
CGEM | GOSS | |
---|---|---|
RSI ODDS (%) | 2 days ago67% | 2 days ago69% |
Stochastic ODDS (%) | 2 days ago83% | 2 days ago81% |
Momentum ODDS (%) | 2 days ago79% | 2 days ago77% |
MACD ODDS (%) | 2 days ago86% | 2 days ago87% |
TrendWeek ODDS (%) | 2 days ago73% | 2 days ago82% |
TrendMonth ODDS (%) | 2 days ago70% | 2 days ago88% |
Advances ODDS (%) | 2 days ago72% | 8 days ago81% |
Declines ODDS (%) | 16 days ago88% | 12 days ago87% |
BollingerBands ODDS (%) | 2 days ago85% | N/A |
Aroon ODDS (%) | 2 days ago71% | 2 days ago89% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FDETX | 22.95 | 0.26 | +1.15% |
Fidelity Advisor Capital Development O | |||
RYCSX | 31.38 | 0.25 | +0.80% |
Rydex Telecommunications C | |||
SBHAX | 21.18 | 0.16 | +0.76% |
Segall Bryant & Hamill All Cap Instl | |||
APHQX | 15.42 | 0.01 | +0.06% |
Artisan Mid Cap Value Institutional | |||
EISRX | 22.45 | N/A | N/A |
Carillon ClariVest Intl Stock R3 |
A.I.dvisor indicates that over the last year, CGEM has been loosely correlated with MDGL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEM jumps, then MDGL could also see price increases.
Ticker / NAME | Correlation To CGEM | 1D Price Change % | ||
---|---|---|---|---|
CGEM | 100% | +2.79% | ||
MDGL - CGEM | 50% Loosely correlated | +6.38% | ||
GOSS - CGEM | 45% Loosely correlated | -4.06% | ||
ORMP - CGEM | 42% Loosely correlated | +0.43% | ||
ATXI - CGEM | 37% Loosely correlated | +0.21% | ||
PDSB - CGEM | 35% Loosely correlated | +2.41% | ||
More |
A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.
Ticker / NAME | Correlation To GOSS | 1D Price Change % | ||
---|---|---|---|---|
GOSS | 100% | -4.06% | ||
MEIP - GOSS | 46% Loosely correlated | N/A | ||
CGEM - GOSS | 45% Loosely correlated | +2.79% | ||
VIR - GOSS | 44% Loosely correlated | +13.18% | ||
SYRE - GOSS | 41% Loosely correlated | -1.35% | ||
APVO - GOSS | 41% Loosely correlated | -12.48% | ||
More |